Skip to main content
Top
Published in: Clinical & Experimental Metastasis 1/2007

01-03-2007 | Research Paper

Clinical and radiological evaluation of patients with lytic, mixed and sclerotic bone metastases from solid tumors: is there a correlation between clinical status of patients and type of bone metastases?

Authors: Vassilios Vassiliou, Christine Kalogeropoulou, Theodoros Petsas, Michael Leotsinidis, Dimitrios Kardamakis

Published in: Clinical & Experimental Metastasis | Issue 1/2007

Login to get access

Abstract

Purpose To investigate the association between the clinical status of patients with metastatic bone disease and the type of bone metastases. Patients and methods 80 patients with skeletal metastases underwent both clinical and radiological assessments. Bone lesions were evaluated with computed tomography (CT), and patients were separated into three groups: lytic, mixed, sclerotic. Bone density of each lesion was measured in Hounsfield units (HU). Results Patients with osteolytic lesions had the highest mean pain score with 8.1 ± 2.2 points, the least mean scores for quality of life (QoL) and performance status (PS) with 31.4 ± 14.6 and 58.6 ± 9.7 points respectively, the highest percentage and mean opioid consumption (100% and 220.9 mg of oral daily morphine equivalent respectively), and the least mean bone density (116.3 ± 40.4 HU). On the contrary, the group with sclerotic metastases had the least mean pain score with 4.6 ± 1.3 points, the highest mean scores of QoL and PS (61.1 ± 15.5 and 66.6 ± 10 points respectively), the least percentage and mean opioid requirement (55.5% and 170.6 mg respectively), and the highest mean bone density (444 ± 86.6 HU). The differences between the three groups were statistically significant for all parameters evaluated, apart from performance status between the sclerotic and mixed groups. The correlation coefficients were statistically significant between all parameters investigated. Bone density had a strong negative correlation with pain. Conclusion Our results show a clear correlation between the type of bone metastases and the clinical status of patients. Patients with excessive bone resorption suffer the most, and may be given priority in treatment. CT proved to be a practical and efficient method to investigate and classify metastatic bone lesions.
Literature
1.
go back to reference Brown HK, Healy JH (2001) Metastatic cancer in bone. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer–principles and practice of oncology, 6 edn. Lippincott Williams and Wilkins, Philadelphia, pp 2713–2729 Brown HK, Healy JH (2001) Metastatic cancer in bone. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer–principles and practice of oncology, 6 edn. Lippincott Williams and Wilkins, Philadelphia, pp 2713–2729
2.
go back to reference Body JJ (1992) Metastatic bone disease: clinical and therapeutic aspects. Bone 13:557–562CrossRef Body JJ (1992) Metastatic bone disease: clinical and therapeutic aspects. Bone 13:557–562CrossRef
3.
go back to reference Mauskop A, Foley KM (1998) Control of pain. In: Harrigton KD (ed) Orthopedic management of metastatic bone disease. CV Mosby, St Lewis, pp 121–137 Mauskop A, Foley KM (1998) Control of pain. In: Harrigton KD (ed) Orthopedic management of metastatic bone disease. CV Mosby, St Lewis, pp 121–137
4.
go back to reference Pecherstorfer M, Vesely M (2000) Diagnosis and monitoring of bone metastases: clinical means. In: Body JJ (ed) Tumor bone disease and osteoporosis in cancer patients. Marcel Dekker, Inc., New York, pp 97–129 Pecherstorfer M, Vesely M (2000) Diagnosis and monitoring of bone metastases: clinical means. In: Body JJ (ed) Tumor bone disease and osteoporosis in cancer patients. Marcel Dekker, Inc., New York, pp 97–129
5.
go back to reference Vinholes JJ, Purohit OP, Abbey ME et al (1997) Relationships between biochemical and symptomatic response in a double–blind randomized trial of pamidronate for metastatic bone disease. Ann Oncol 8:1243–1250PubMedCrossRef Vinholes JJ, Purohit OP, Abbey ME et al (1997) Relationships between biochemical and symptomatic response in a double–blind randomized trial of pamidronate for metastatic bone disease. Ann Oncol 8:1243–1250PubMedCrossRef
6.
go back to reference Peh WCG, Muttarak M (2003) Clinics in diagnostic Imaging (82). Singapore Med J 44(2):101–105PubMed Peh WCG, Muttarak M (2003) Clinics in diagnostic Imaging (82). Singapore Med J 44(2):101–105PubMed
7.
go back to reference Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176PubMedCrossRef Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176PubMedCrossRef
8.
go back to reference Maisano R, Pergolizzi S, Cascinu S (2001) Novel therapeutic approaches to cancer patients with bone metastasis. Crit rev Oncol/Hematol 40:239–250CrossRef Maisano R, Pergolizzi S, Cascinu S (2001) Novel therapeutic approaches to cancer patients with bone metastasis. Crit rev Oncol/Hematol 40:239–250CrossRef
9.
go back to reference Iddon J, Byrne G, Bundred NJ (1999) Bone metastasis in breast cancer: the role of parathyroid hormone related protein. Surg oncol 8:13–25PubMedCrossRef Iddon J, Byrne G, Bundred NJ (1999) Bone metastasis in breast cancer: the role of parathyroid hormone related protein. Surg oncol 8:13–25PubMedCrossRef
10.
go back to reference Bonadonna G, Rossi A, Valagussa P et al (1997) The CMF program for operable breast cancer with positive axillary nodes. Cancer 39:2904–2915CrossRef Bonadonna G, Rossi A, Valagussa P et al (1997) The CMF program for operable breast cancer with positive axillary nodes. Cancer 39:2904–2915CrossRef
11.
go back to reference Chow E, Holden L, Rubenstein J et al (2004) Computed Tomography (CT) evaluation of breast cancer patients with osteolytic bone metastases undergoing palliative radiotherapy–a feasibility study. Radiother Oncol 70:291–294PubMedCrossRef Chow E, Holden L, Rubenstein J et al (2004) Computed Tomography (CT) evaluation of breast cancer patients with osteolytic bone metastases undergoing palliative radiotherapy–a feasibility study. Radiother Oncol 70:291–294PubMedCrossRef
12.
go back to reference Karnofsky DA, Abelmann WH, Craver LF et al (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1:634CrossRef Karnofsky DA, Abelmann WH, Craver LF et al (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1:634CrossRef
13.
go back to reference Aaronson NK, Ahmedzai S, Bergman B et al (1993) For the European organization for research and treatment of cancer QLQ-C30: a quality of life instrument for use in international trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef Aaronson NK, Ahmedzai S, Bergman B et al (1993) For the European organization for research and treatment of cancer QLQ-C30: a quality of life instrument for use in international trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef
14.
go back to reference Storto G, Klain M, Paone G et al (2006) Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39:35–41PubMedCrossRef Storto G, Klain M, Paone G et al (2006) Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39:35–41PubMedCrossRef
15.
go back to reference Vassiliou V, Kalogeropoulou C, Christopoulos C et al. (2007) Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys 67(1): 264–272PubMed Vassiliou V, Kalogeropoulou C, Christopoulos C et al. (2007) Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys 67(1): 264–272PubMed
16.
go back to reference Chow E, Ling A, Davis L et al (2005) Pain flare following external beam radiotherapy and meaningful change in pain scores in the treatment of bone metastases. Radiotherapy Oncol 75:64–69CrossRef Chow E, Ling A, Davis L et al (2005) Pain flare following external beam radiotherapy and meaningful change in pain scores in the treatment of bone metastases. Radiotherapy Oncol 75:64–69CrossRef
17.
go back to reference Umatsu T, Yuen S, Yukisawa S et al (2005) Comparison of FDGPET and SPECT for detection of bone metastases in breast cancer. AJR 184:1266–1273 Umatsu T, Yuen S, Yukisawa S et al (2005) Comparison of FDGPET and SPECT for detection of bone metastases in breast cancer. AJR 184:1266–1273
18.
go back to reference Southard TE, Southard KA (1996) Detection of simulated osteoporosis in maxillae using radiographic texture analysis. IEEE Trans Biom Eng 43:123–132CrossRef Southard TE, Southard KA (1996) Detection of simulated osteoporosis in maxillae using radiographic texture analysis. IEEE Trans Biom Eng 43:123–132CrossRef
Metadata
Title
Clinical and radiological evaluation of patients with lytic, mixed and sclerotic bone metastases from solid tumors: is there a correlation between clinical status of patients and type of bone metastases?
Authors
Vassilios Vassiliou
Christine Kalogeropoulou
Theodoros Petsas
Michael Leotsinidis
Dimitrios Kardamakis
Publication date
01-03-2007
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 1/2007
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-007-9056-z

Other articles of this Issue 1/2007

Clinical & Experimental Metastasis 1/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine